222035-13-4 Usage
Description
CDK2 INHIBITOR II, also known as a 3-(benzylidne)indolin-2-one analog, is a potent, cell-permeable, ATP-competitive, and selective inhibitor of cyclin-dependent kinase 2 (Cdk2). CDK2 INHIBITOR II works by selectively and potently inhibiting Cdk2, which plays a crucial role in regulating the S phase and G2-M transition during the cell cycle when working with cyclins A or E. The inhibitory action of CDK2 INHIBITOR II is characterized by its cell permeability, reversibility, and ATP-competitive nature, making it a valuable tool in various applications.
Uses
Used in Pharmaceutical Industry:
CDK2 INHIBITOR II is used as a pharmaceutical agent for the development of cancer therapeutics. It targets Cdk2, a key regulator of cell cycle progression, which is often dysregulated in cancer cells. By inhibiting Cdk2, this compound can potentially arrest the cell cycle, leading to the prevention of tumor growth and the promotion of apoptosis in cancer cells.
Used in Research Applications:
In the field of biological and medical research, CDK2 INHIBITOR II serves as a valuable research tool for studying the role of Cdk2 in cell cycle regulation and its involvement in various cellular processes. It can be used to investigate the molecular mechanisms underlying the regulation of cell cycle progression, as well as to identify potential therapeutic targets for the treatment of cancer and other diseases associated with dysregulated cell cycle control.
Used in Drug Development:
CDK2 INHIBITOR II is employed as a lead compound in the development of novel drugs targeting Cdk2 for the treatment of cancer. Its potent and selective inhibition of Cdk2 makes it an attractive starting point for the design and synthesis of new compounds with improved pharmacological properties, such as increased potency, selectivity, and bioavailability. These new compounds can then be further optimized and tested for their potential therapeutic efficacy in preclinical and clinical studies.
Used in Drug Delivery Systems:
To enhance the efficacy and bioavailability of CDK2 INHIBITOR II, various drug delivery systems can be employed. These systems can include organic and metallic nanoparticles, liposomes, or other advanced delivery platforms, which aim to improve the compound's solubility, stability, and targeted delivery to cancer cells. By utilizing these drug delivery systems, the therapeutic potential of CDK2 INHIBITOR II can be maximized, while minimizing potential side effects and toxicity associated with its use.
Check Digit Verification of cas no
The CAS Registry Mumber 222035-13-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,2,2,0,3 and 5 respectively; the second part has 2 digits, 1 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 222035-13:
(8*2)+(7*2)+(6*2)+(5*0)+(4*3)+(3*5)+(2*1)+(1*3)=74
74 % 10 = 4
So 222035-13-4 is a valid CAS Registry Number.
222035-13-4Relevant articles and documents
3-Hydrazinoisatin-based benzenesulfonamides as novel carbonic anhydrase inhibitors endowed with anticancer activity: Synthesis, in vitro biological evaluation and in silico insights
Abo-Ashour, Mahmoud F.,Eldehna, Wagdy M.,Nocentini, Alessio,Bonardi, Alessandro,Bua, Silvia,Ibrahim, Hany S.,Elaasser, Mahmoud M.,Kry?tof, Vladimír,Jorda, Radek,Gratteri, Paola,Abou-Seri, Sahar M.,Supuran, Claudiu T.
, (2019/10/19)
Herein we describe the design and synthesis of two series of sulfonamides featuring N-unsubstituted (4a-c) or N-substituted (7a-o) isatin moieties (as tails) connected to benzenesulfonamide moiety via a hydrazine linker. All the prepared sulfonamides (4a-c and 7a-o) showed potent inhibitory activities toward transmembrane tumor-associated human (h) carbonic anhydrase (hCA, EC 4.2.1.1) isoforms, IX and XII with KI range (8.3–65.4 nM) and (11.9–72.9 nM), respectively. Furthermore, six sulfonamides (7e, 7i, 7j, 7m, 7n and 7o) were assessed for their anti-proliferative activity, according to US-NCI protocol, toward a panel of sixty cancer cell lines. Compounds 7j and 7n were the most promising counterparts in this assay displaying broad spectrum anti-proliferative activity toward diverse cell lines. Also, sulfonamide 7n significantly inhibited clonogenicity of HCT-116 cells in a concentration dependent manner in the colony forming assay. Moreover, molecular modeling studies were performed to gain insights for the plausible binding interactions and affinities for the target isatin-based sulfonamides (4a-c and 7a-o) within hCA isoforms II and IX active sites.
